and the Departments of2Ophthalmology and 3Pathology, Western Infirmary, Glasgow SUMMARY Tests of cell mediated immunity (one and two stage leucocyte migration inhibition assays) and humoural immunity (membrane immunofluorescence and serum effects on leucocyte migration) were done with leucocytes and sera from 36 patients with uveal melanoma, five with conjunctival melanoma, 21 with non-malignant ocular disease, and 189 with cutaneous melanoma. Cell mediated reactivity with melanoma extracts and serum reactivity with cultured melanoma cells were significantly more frequent in the melanoma patients, but control donor reactivity was also relatively high. Maximum reactivity was found with cells or serum from those patients in whom, on pathological examination, the intraocujar melanoma had penetrated the sclera and in patients with conjunctival melanoma. Maximum separation of melanoma patients from control donors was achieved by consideration of the results of several tests done simultaneously. These immunopathological studies were made during the period from 1972 to 1978. At follow-up in 1983 four of the five patients suffering from conjunctival melanoma had died from metastases, and 10 of the 36 with uveal melanoma had died from metastatic disease. The immunological reactions, while of some value in separating melanoma patients from those without melanoma, did not predict whether a particular patient with uveal melanoma would die of metastatic disease or would survive.
In eyes with clear media malignant melanoma of the uveal tract seldom presents a significant diagnostic problem. This is because of the application of supplementary techniques such as 32P uptake, fluorescein angiography, and ultrasonography.'2 However, with opaque media, and occasionally even with clear media, assessment of a possible tumour may remain difficult. Current and fundamental problems include a basic lack of understanding of the factors that govern the biological behaviour of ocular melanoma. In particular there is no possibility of our being able to assess the chances of long-term survival for the individual patient, though statistical analysis of large numbers of enucleated eyes has emphasised the importance in prognosis of factors such as tumour size, cell type, and the presence or absence of extraocular spread at enucleation.3 A factor to be taken into account when the nature and mechanisms of metastatic disease are under consideration is the host-tumour relationship. This is also relevant to the Correspondence to Alistair J Cochran, MD. therapeutic techniques currently under investigation (local excision, irradiation modes of various types, light and laser coagulation etc.). ' 2 The immune status of patients with uveal melanoma has been the subject of intensive research for some 15 years,4 and studies of humoural immunity or cell mediated immunity have shown that in a significant proportion of patients with uveal melanoma there is in-vitro evidence of tumour related immune reactivity.
However, similar in-vitro tests also show immune reactivity to melanoma antigens in a smaller percentage of control patients. In an attempt to refine immunopathological investigations we correlated simultaneous tests of humoural and cell mediated immunity in 36 patients with uveal melanoma and five patients with conjunctival melanoma during the period 1972-8. The results are presented in relation to the pathological findings and survival data for patients over not less than five years. The results from ocular melanoma patients are compared with data compiled for patients with cutaneous melanoma. 171 A J Cochran, WS 
Results
The data were analysed for melanomas arising at different sites within the eyeball and on the conjunctiva (Table 1) . A majority of patients reacted (a) in the leucocyte migration assay when medium supplemented with fetal calf serum was used to suspend the melanoma antigen and (b) in the membrane immunofluorescence test. A smaller but still substantial proportion of patients' leucocytes were inhibited by melanoma antigens suspended in medium supplemented with autologous serum in the leucocyte migration assay. A smaller proportion showed leucocyte migration inhibition in medium supplemented with autologous serum without added melanoma antigen. While reactivity seemed higher in the conjunctival melanoma patients, the number of such patients studied was small.
Reactions of ocular melanoma patients compared with controls. The migration of leucocytes from melanoma patients was frequently inhibited by exposure to formalinised melanoma cells (FMC) in the one-stage capillary migration assay with fetal calf In a small group of ocular control donors leucocyte inhibition in medium supplemented with AS was not significantly less frequent (3 out of 9, 33%) than that observed with the melanoma patients (19 out of 32, 59%).
When leucocytes were exposed to AS without the addition of FMC, uveal melanoma patients' leucocytes were inhibited moderately frequently (13 out of 41, 32%), a rate that did not differ significantly from that of cutaneous melanoma patients (42 out of 89, 48%) or ocular controls (4 out of 21, 19%), though non-ocular controls (14 out of 100, 14%-p<0025) reacted significantly less frequently.
Uveal melanoma patients were tested in a twostage assay, and although the frequency of reaction (3 out of 9, 33%) was higher than that observed with non-ocular control donors (5 out of 38, 13% -NS), it was significantly lower than that observed with cutaneous melanoma (31 out.of 65 (Table 3 ). Regardless of the immunological technique employed the reaction frequency of patients with evidence of extraocular extension was higher than that of patients in whom the tumour was confined to the globe. The differences were statistically significant with the exception of those observed with the leucocyte migration assay in the presence of autologous serum. Follow-up of the patients in this study to 1983, five years or more, has shown that four of five with conjunctival melanoma and 10 of 36 with intraocular melanoma died from metastatic melanoma. The pattern of immunological tests did not have significant characteristics in the individual patients who subsequently died from metastases.
Correlation of immunological reactivity ofpatients uveal melanoma patients and control donors showed that a higher proportion of the tumour patients reacted positively in the leucocyte migration assay in the presence of tumour antigen, in the membrane immunofluorescence test, and in the assay studying the effect of autologous serum on leucocyte migration in the absence ofadded antigen (Table 4) . A relatively high proportion of the ocular control donors also reacted, especially in the first two tests. We therefore combined the patterns of reaction in the different tests in various ways to see whether this would better separate the two populations and provide a more specific indication of the presence of ocular melanoma. This was achieved when we compared those who reacted in two or three tests. However, with three tests the absolute proportion of ocular melanoma patients who reacted dropped to an unacceptably low 31%. When we combined reactivity in the leucocyte migration assay in the presence of antigen and in the immunofluorescence technique, we found that 56% of ocular melanoma patients reacted in both tests, whereas only one of nine (11%) of the ocular controls reacted in both. This was the optimum combination of tests that minimised 'false positive' reactions in controls.
Discussion
There is now considerable evidence that in-vitro tests show tumour-directed antibodies in the serum of patients with uveal or conjunctival melanoma. In assessing individual tests we found that all were more often positive in patients with ocular melanoma than in the control groups. The high frequency of reaction of the ocular melanoma patients in both the one-stage leucocyte migration assay against melanoma-associated antigens and the membrane immunofluorescence technique is encouraging. However, there was also a comparatively high frequency of reaction in control donors, particularly the ocular control donors, in these tests. Discrimination is considerably improved when we assess the concurrence of positive results in the leucocyte migration assay and the membrane immunofluorescence test done simultaneously. This gave excellent separation of ocular melanoma patients and the control donors, but unfortunately the absolute frequency of reaction in the melanoma group dropped to 53% compared with 11% id the control group. Thus with refinements in technique there is some prospect of an immunological profile being of diagnostic value in patients who have opaque media or a questionable diagnosis.
Little difference was found between groups of people subdivided by sex, site of primary tumour, and gross and microscopic features of the tumours, and this supports previous findings.I&lS A striking exception is the fact that patients whose tumours showed transcleral and episcleral extension were very much more often reactive than patients whose tumours were confined to the globe. This finding is in keeping with the view that the interior of the eye is to some extent an immunologically privileged site and suggests that the autoimmunising capacity of the cells of an ocular malignant melanoma is greatly increased once these cells penetrate beyond the sclera.'9 The failure of the tests to provide prognostic indicators was disappointing, as no correlation was found with survival rate.
In summary the studies undertaken support previous reports of autoimmunogenic tumourassociated antigens on malignant melanomas in general and ocular malignant melanomas in particular. In our view the tests are not at present applicable in a routine fashion as diagnostic or prognostic aids in malignant melanoma. This. opinion is based on the technical complexity of tests employed and also the high levels of false positivity and false negativity. We therefore require more refined tests that can be applied on a large scale and which would have a markedly higher rate of reaction within the melanoma patients and a considerably lower reaction frequency in the control donors. False positive results suggest that inflammation or other non-tumorous processes may lead to transient immune responses. Further purification of ocular melanoma antigens and sequential studies may assist in refining the specificity of the tests employed, and perhaps access to free antigen in the aqueous humour might produce a more reliable source of information.
